Consultant Department of Cardiovascular Medicine at Mayo Clinic Rochester, Minnesota, United States
Disclosure(s):
Jeffrey Geske, MD: No relevant disclosure to display
Presentation Description / Summary: State-of-the-art in hypertrophic cardiomyopathy in humans: clinical practice updates and current clinical research
Learner Outcomes:
1. Outline current practice standards for treatment of hypertrophic cardiomyopathy in humans, spanning lifestyle modifications, pharmacotherapy, and septal reduction therapy 2. Review the evolving role of myosin inhibitors in hypertrophic cardiomyopathy 3. Discuss risk stratification schema of sudden cardiac death in hypertrophic cardiomyopathy in humans, recognizing discordance of symptoms and death risk
Learning Objectives:
Outline current practice standards for treatment of hypertrophic cardiomyopathy in humans, spanning lifestyle modifications, pharmacotherapy, and septal reduction therapy
Review the evolving role of myosin inhibitors in hypertrophic cardiomyopathy
Discuss risk stratification schema of sudden cardiac death in hypertrophic cardiomyopathy in humans, recognizing discordance of symptoms and death risk
